Analysts think GUTS stock price could increase by 656%
Jan 27, 2025, 12:25 PM
-30.62%
What does GUTS do
Fractyl Health, headquartered in Burlington, Massachusetts, focuses on treating metabolic diseases like type 2 diabetes and obesity with its Revita DMR System and Rejuva gene therapy. The company went public on February 2, 2024, and employs 102 full-time staff.
4 analysts think GUTS stock price will increase by 656.46%. The current median analyst target is $15.81 compared to a current stock price of $2.09. The lowest analysts target is $13.13 and the highest analyst target is $18.90.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.